Exercise during chemotherapy may help immune cells fight cancer – patients invited to join new trial
Exercising during chemotherapy and before surgery may help the body send more immune cells into cancerous tumours, according to a first-of-its-kind pilot study from the University of Surrey and Royal Surrey NHS Foundation Trust.
In a study published in the Journal of Sport and Health Sciences, the research team conducted a randomised controlled trial with 22 people diagnosed with oesophageal adenocarcinoma – a type of oesophageal cancer. These patients were recruited from Royal Surrey NHS Foundation Trust, home to one of the country’s leading cancer centres. Eleven participants took part in a 16-week structured exercise programme (known as “prehabilitation”), while the other eleven did not. The programme included two supervised exercise sessions per week during the chemotherapy period (for about eight weeks), followed by a second phase of exercise leading up to surgery.
After surgery, the research team analysed each patients’ tumour samples to measure immune cells using multispectral immunohistochemistry. They also studied gene activity using a platform called NanoString. Finally, they assessed each patients’ aerobic fitness through tests carried out before, during and after chemotherapy.
A patient in the clinical trial
There have been a number of animal-based studies showing that exercise can improve immune responses and reduce cancer growth. However, previous studies in humans – mainly focused on prostate or colorectal cancer – have not shown a clear increase in tumour-infiltrating immune cells after exercise, even after multiple sessions.
OPTIMUS aims to recruit 50 patients who are scheduled for surgery after neoadjuvant chemotherapy for oesophageal adenocarcinoma.
Patients will be randomised into one of two groups: either an exercise group similar to the published study that improved the immune response to the tumour, or a higher intensity exercise group that may increase the immune response further.
So far, seven patients have completed OPTIMUS, and in some cases, the tumour was undetectable during surgery, which is only found in around 6% of patients. While these are early results, they are quite remarkable. Importantly, patients are fitter for surgery and are dealing with the stress of surgery and recovery much better.Mr Charles Rayner, co-first author of the study and Fellow in oesophago-surgery from Royal Surrey NHS Foundation Trust
These are exciting findings which support the importance of preoperative exercise training for patients undergoing cancer surgery at Royal Surrey. The feedback from our patients has been overwhelmingly positive with some patients who would otherwise not have been able to undergo this life saving surgery, improving their fitness to such a degree that they have now had successful procedures.Mr Nima Abbassi-Ghadi, Senior author of the study and Consultant oesophago-gastric surgeon at Royal Surrey NHS Foundation Trust
One of the OPTIMUS participants said:
When you first get a cancer diagnosis one tends to clutch at anything which might make a difference, so when I was asked if I wanted to take part in the OPTIMUS study I jumped at the chance. I did this as an already active person but had no idea how large a part the OPTIMUS trial would play during my chemo and in preparation for my recovery from surgery.An OPTIMUS participant
Cancer and its treatment take away many things which give us normality; our jobs, our health, our appearance, quality time with family, whilst introducing myriad appointments, chemo side effects, stress over incomes, difficult questions and conversations with children and the very obvious chance of early death. As a cancer patient, one has little or no agency over any of these factors.
What the OPTIMUS trial gave me was one thing over which I had control. It is an enthusiastic environment, staffed by dedicated young people, all simultaneously trying to help us and to push scientific understanding of the effect of exercise on cancer outcomes. Like most things in life, it is the people running the day-to-day that make this trial special.
They both help you to achieve the best outcome for you (age spread ~57-84), pushing you where appropriate, but they also have the emotional intelligence to know when you need a tissue and an arm round the shoulder, as cancer is an emotional roller coaster.
Although I am a reasonably determined person anyway, I can categorically say that, along with the oncologists and surgeons that saved my life, the Optimus team made the biggest qualitative difference to my cancer journey and recovery."
People can join the study if they are being treated at the Royal Surrey Cancer Centre and should ask their oncology or surgical teams about the study. Alternatively, they can email Dr Bartlett and Dr Annels directly at d.bartlett@surrey.ac.uk or n.annels@surrey.ac.uk.
Funding for the research [IIG_FULL_2023_029] was obtained from the World Cancer Research Fund (WCRF UK), as part of the World Cancer Research Fund International grant programme.
###
Note to editors
- Dr Nicola Annels and Dr David Bartlett are available for interview; please contact mediarelations@surrey.ac.uk to arrange.
- The full paper is available at https://doi.org/10.1016/j.jshs.2025.101063
- An image of Dr Nicola Annels and Dr David Bartlett is available upon request
Related sustainable development goals
Share what you've read?
Featured Academics
Media Contacts
External Communications and PR team
Phone: +44 (0)1483 684380 / 688914 / 684378
Email: mediarelations@surrey.ac.uk
Out of hours: +44 (0)7773 479911